Table 4.

Association between infiltrating immune cells and two-year overall mortality in HIV-related DLBCL patients, crude and adjusted for International Prognostic Index (IPI).

HIV-infected patients (n=80) Stromal immune cells	Crude	Adjusted for IPI, germinal center phenotype and DLBCL variant
	Odds ratio (95% CI)	Odds ratio (95% CI)	P-value
CD4 (reference: <1%)
≥1%	0.49 (0.18–1.31)	0.43 (0.14–1.31)	0.14
CD8 (reference: <10%)
10–24%	0.41 (0.12–1.37)	0.37 (0.10–1.31)	0.12
≥25%	0.37 (0.13–1.06)	0.30 (0.09–0.97)	0.05
≥10% vs. <10%	0.38 (0.15–0.99)	0.33 (0.12–0.92)	0.04
FOXP3 (reference: <10%)
10–24%	0.97 (0.32–2.95)	0.73 (0.21–2.51)	0.62
≥ 25%	0.36 (0.04–3.33)	0.14 (0.01–1.68)	0.12
CD68 (reference: <10%)
10–24%	0.86 (0.30–2.48)	1.04 (0.33–3.21)	0.95
≥ 25%	2.49 (0.74–8.34)	2.14 (0.48–9.43)	0.32
≥ 25% vs. <25%	2.65 (0.86–8.20)	2.11 (0.54–8.14)	0.28